SHREVEPORT, La. - In 2011, Shane Sumlin's life changed overnight after being diagnosed with a rare neurological disorder ...

Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced its interim report for January-March 2025.

A week later, Abraham woke up in the middle of the night and tried to stand. She collapsed to the floor, struggling to ...

As it advances a monoclonal antibody targeting Guillain-Barré syndrome (GBS), Annexon Biosciences is embarking on another ...

The primary endpoint, outcome on the GBS Disability Score (GBS-DS) at 8 weeks, showed 29% of patients treated with tanruprubart at a dose of 30 mg/kg recovered to a healthy state with a score of 0 or ...

Megyn Kelly, the American journalist, regrets her decision to get the Covid-19 vaccine, citing an autoimmune diagnosis ...

SAN DIEGO -- A single dose of investigational tanruprubart resulted in rapid, sustained improvement in disability compared with placebo in patients with Guillain-Barré syndrome (GBS), a phase III ...

Strong product sales and key progress in pipeline catalysts LUND, Sweden, April 24, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" or the "Company" (Nasdaq Stockholm: HNSA), today announced ...

Freddie Freeman's wife Chelsea is giving a positive update on her 4-year-old son Max after he was hospitalized over the ...

As part of Patient Experience Week, Stewart Memorial Community Hospital is shining a spotlight on the remarkable care ...

Annexon achieved primary endpoints in two Phase 3 studies for tanruprubart in treating Guillain-Barre Syndrome, setting the stage for a pre-BLA meeting ...